1. Home
  2. IPHA vs EVC Comparison

IPHA vs EVC Comparison

Compare IPHA & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • EVC
  • Stock Information
  • Founded
  • IPHA 1999
  • EVC 1996
  • Country
  • IPHA France
  • EVC United States
  • Employees
  • IPHA N/A
  • EVC N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • EVC Broadcasting
  • Sector
  • IPHA Health Care
  • EVC Industrials
  • Exchange
  • IPHA Nasdaq
  • EVC Nasdaq
  • Market Cap
  • IPHA 191.0M
  • EVC 166.9M
  • IPO Year
  • IPHA 2019
  • EVC 2000
  • Fundamental
  • Price
  • IPHA $2.17
  • EVC $1.94
  • Analyst Decision
  • IPHA Strong Buy
  • EVC Hold
  • Analyst Count
  • IPHA 1
  • EVC 1
  • Target Price
  • IPHA $11.50
  • EVC $1.75
  • AVG Volume (30 Days)
  • IPHA 6.6K
  • EVC 248.3K
  • Earning Date
  • IPHA 09-12-2024
  • EVC 10-31-2024
  • Dividend Yield
  • IPHA N/A
  • EVC 10.00%
  • EPS Growth
  • IPHA N/A
  • EVC N/A
  • EPS
  • IPHA N/A
  • EVC N/A
  • Revenue
  • IPHA $36,202,722.00
  • EVC $1,126,331,000.00
  • Revenue This Year
  • IPHA N/A
  • EVC N/A
  • Revenue Next Year
  • IPHA $105.84
  • EVC N/A
  • P/E Ratio
  • IPHA N/A
  • EVC N/A
  • Revenue Growth
  • IPHA N/A
  • EVC 65.95
  • 52 Week Low
  • IPHA $1.81
  • EVC $1.33
  • 52 Week High
  • IPHA $3.15
  • EVC $4.41
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 44.65
  • EVC 47.27
  • Support Level
  • IPHA $2.22
  • EVC $1.88
  • Resistance Level
  • IPHA $2.35
  • EVC $2.08
  • Average True Range (ATR)
  • IPHA 0.13
  • EVC 0.08
  • MACD
  • IPHA -0.01
  • EVC -0.00
  • Stochastic Oscillator
  • IPHA 20.59
  • EVC 30.00

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

Share on Social Networks: